


[View this email in your browser](#)



RELIVE *flash*

No.8 - March 2024

RELIVE: we are almost there!

By January 31, a total of 337 patients have been documented in the RELIVE database. This means that we have even gone beyond the goal of 300 patients stated in the protocol, thanks to all of you who have invested so much effort into the study! And a few countries are still working on the documentation of some of their patients. The latest addition comes from Denmark where Rigshospitalet has joined the study at the beginning of 2024.

- The study is now running in the following countries: Australia, Belgium, Canada, Denmark, France, Germany, Hong Kong, Italy, Japan, Poland, Spain, Switzerland, The Netherlands, UK and the US.
- 357 patients have been registered by the following sites:

US (Boston, Cincinnati, Spokane, UCSF, Salt Lake City, Houston)	69
Japan (22 institutions)	48
France (IGR Villejuif for French sites)	38
Hong Kong Children's Hospital	37
Prinses Maxima Centrum, Netherlands	33
Hospital for Sick Children, Toronto, Canada	31
Munich (pts from several institutions), Germany	31
Australia (Brisbane, Newcastle, Sydney, Adelaide, Perth)	24
Gdansk, Poland	11
Spain (Málaga, Sevilla, Barcelona, Valencia)	10
Belgium	8
Denmark	7
Switzerland (Geneva, Lausanne and Zurich)	6
Italy (Milano and Bari)	4

More patients are expected, especially from the UK.

The timelines for the data finalization had to be postponed again, and data monitoring continues throughout Spring 2024.

Please note that the RELIVE database remains open, and we strongly recommend that you continue to register patients or update the follow-up of already documented patients.

Next Steps

- During the **SIOPEL Spring Meeting of March 13-16 in Gdansk**, first and preliminary results will be presented on hepatoblastoma patients, which constitute the majority of all patients. There will be an open Steering Committee meeting on March 13, 16:30 – 18:00, all RELIVE investigators are kindly invited to attend and to discuss results with all of us. A short update of the study will also be presented on Thursday morning in the plenary.
- During Spring, the database will be cleaned in collaboration with the Geneva Team and the investigators and CRAs from all participating countries. Thereafter, the Steering Committee will oversee the evaluation and publication(s).

First RELIVE publication out!

[“The RELIVE Consortium for Relapsed or Refractory Pediatric Hepatoblastoma and Hepatocellular Carcinoma: A Scoping Review of the Problem and a Proposed Solution”](#) has just been published in *Lancet eClinicalMedicine* Vol. 69, February 15, 2024, and can be found on the [RELIVE](#) website.

A series of authors led by Allison O'Neill and Marc Ansari have developed this manuscript over the past two years. The *Research in Context* box states among others: “This scoping review was undertaken to compile all published literature describing agents trialed for relapsed or refractory pediatric HB or HCC. We demonstrate that there are no available studies properly powered or randomized to identify or conclude treatment efficacy”.

It's time to design your email.

Now that you've selected a template, you'll define the layout of your email and give your content a place to live by adding, rearranging, and deleting content blocks.

When you're ready to change the look of your email, take a look through the “style” tab to set background colors, borders, and other styles.

If you need a bit of inspiration, you can [see what other Mailchimp users are doing](#), or [learn about email design](#) and blaze your own trail.